Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vilanterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 0.82 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.82 |
| ▸ | ADRB3 | P13945 | 15/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.81 |
| ▸ | HTR2A | P28223 | 2/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.81 |
| ▸ | MLNR | O43193 | 1/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | DRD1 | P21728 | 1/20 | 0.81 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.81 |
| ▸ | MC3R | P41968 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.81 |
| ▸ | GHSR | Q92847 | 1/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vilanterol SCHEMBL164639 | 1.00 | ADRB2 (0.82) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL29352172 | 1.00 | ADRB2 (0.82) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL29150309 | 0.91 | ADRB2 (0.86) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| SCHEMBL23734612 | 0.91 | ADRB2 (0.68) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Acetic Acid SCHEMBL925230 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL29448201 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL925229 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL15614685 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL142630 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| SCHEMBL17031687 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4452924-B1 | PROCESS TO PREPARE VILANTEROL TRIFENATATE | HOVIONE SCIENTIA LTD (IE) | 2025-12-03 | — | — | EP | disclosed |
| US-12396986-B2 | Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist | GLAXO GROUP LIMITED (GB) | 2025-08-26 | — | — | US | disclosed |
| US-20250051261-A1 | Process to Prepare Vilanterol Trifenatate | HOVIONE SCIENTIA LIMITED (IE) | 2025-02-13 | — | — | US | disclosed |
| CN-118715200-A | Process for preparing vilantrum Luo San phenylacetate | 好利安科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| EP-4188905-B1 | METHOD FOR THE PURIFICATION OF VILANTEROL TRIFENATATE | INKE SA (ES) | 2024-09-11 | — | — | EP | disclosed |
| CN-115745945-B | Method for preparing vilantro intermediate by one-pot method | 奥锐特药业股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-114441677-B | Method for simultaneously detecting multiple gene impurities of vilanafloc triphenylacetate | 上海方予健康医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240041846-A1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | GLAXO GROUP LIMITED (GB) | 2024-02-08 | — | — | US | disclosed |
| US-20230286898-A1 | METHOD FOR THE PURIFICATION OF VILANTEROL TRIFENATATE | INKE, S.A. (ES) | 2023-09-14 | — | — | US | disclosed |
| WO-2023118833-A1 | PROCESS TO PREPARE VILANTEROL TRIFENATATE | HOVIONE SCIENTIA LIMITED (IE) | 2023-06-29 | — | — | WO | disclosed |
| EP-4188905-A1 | METHOD FOR THE PURIFICATION OF VILANTEROL TRIFENATATE | INKE, S.A. (ES) | 2023-06-07 | — | — | EP | disclosed |
| CN-116209654-A | Method for purifying vilantro triphenyl acetate | INKE股份公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-115745945-A | Method for preparing vilanterol intermediate by one-pot method | 奥锐特药业股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-114441677-A | Method for simultaneously detecting multiple gene impurities of vilanterol trithionate | 上海方予健康医药科技有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-113121492-A | Vilandiolo intermediate, preparation method and application thereof | 天津药业研究院股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-111807973-B | Preparation method of vilanterol and salt thereof | 上海谷森医药有限公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-111807973-A | Preparation method of vilanterol and salt thereof | 上海谷森医药有限公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-111108091-A | Novel crystalline form of vilanterol triphenylacetate and process for preparing the same | 好利安科技有限公司 | 2020-05-05 | — | — | CN | disclosed |
| CN-111094235-A | Amorphous form of vilanterotricin acetate and process for its preparation | 好利安科技有限公司 | 2020-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051261-A1 | Process to Prepare Vilanterol Trifenatate | AVPR2, CYP2D6, AVPR1B | ADRB2 145/4885ADRB1 144/4885ADRB3 401/4885 |
| US-12396986-B2 | Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist | ADRB2, CHRM3, ADRA2A | ADRB2 1/4885ADRB1 8/4885ADRB3 13/4885 |
| US-20240041846-A1 | COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST | ADRB2, CHRM3, ADRA2A | ADRB2 1/4885ADRB1 11/4885ADRB3 14/4885 |
| US-20230286898-A1 | METHOD FOR THE PURIFICATION OF VILANTEROL TRIFENATATE | MAP2K5, MAP2K7, MAP2K1 | ADRB2 1903/4885ADRB1 1740/4885ADRB3 1674/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ADRB2 205/4885ADRB1 746/4885ADRB3 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.